{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:26:21Z","timestamp":1794119181701,"version":"4.8.0"},"reference-count":37,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"NIH","doi-asserted-by":"publisher","award":["Medical Research Council"],"award-info":[{"award-number":["Medical Research Council"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,6,7]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec id=\"s1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately 30% of patients with the systemic autoimmune\/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeutic Potential by Application of Novel and Systemic Approaches and the Engineering Consortium aims to identify indicators of treatment responses in SLE. This study tested the applicability of calcium-binding S100 proteins in serum and urine as biomarkers for disease activity and response to treatment with rituximab (RTX) in LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>S100A8\/A9 and S100A12 proteins were quantified in the serum and urine of 243 patients with SLE from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) study and 48 controls matched for age using Meso Scale Discovery\u2019s technology to determine whether they perform as biomarkers for active LN and\/or may be used to predict response to treatment with RTX. Renal disease activity and response to treatment was based on BILAG-BR scores and changes in response to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum S100A12 (p&lt;0.001), and serum and urine S100A8\/A9 (p&lt;0.001) levels are elevated in patients with SLE. While serum and urine S100 levels do not correlate with global disease activity (SLE Disease Activity Index), levels in urine and urine\/serum ratios are elevated in patients with active LN. S100 proteins perform better as biomarkers for active LN involvement in patients with SLE who tested positive for anti-double-stranded DNA antibodies. Binary logistic regression and area under the curve analyses suggest the combination of serum S100A8\/A9 and S100A12 can predict response to RTX treatment in LN after 6\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s4\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings from this study show promise for clinical application of S100 proteins to predict active renal disease in SLE and response to treatment with RTX.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001257","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T17:39:22Z","timestamp":1595957962000},"page":"e001257","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Urine and serum S100A8\/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment"],"prefix":"10.1136","volume":"6","author":[{"given":"Jennifer C","family":"Davies","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Midgley","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Donohue","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N","family":"Bruce","sequence":"additional","affiliation":[{"name":"Arc Epidemiology Unit, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Beresford","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"},{"name":"Department of Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-6179","authenticated-orcid":false,"given":"Christian M","family":"Hedrich","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"},{"name":"Department of Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2025090312552378000_6.2.e001257.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.05.006"},{"key":"2025090312552378000_6.2.e001257.2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3897"},{"key":"2025090312552378000_6.2.e001257.3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3928\/0090-4481-19820401-10","article-title":"Systemic lupus erythematosus","volume":"11","author":"Rothfield","year":"1982","journal-title":"Pediatr Ann"},{"key":"2025090312552378000_6.2.e001257.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.78"},{"key":"2025090312552378000_6.2.e001257.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.5.409"},{"key":"2025090312552378000_6.2.e001257.6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/0961203319847275","article-title":"Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort","volume":"28","author":"Reppe Moe","year":"2019","journal-title":"Lupus"},{"key":"2025090312552378000_6.2.e001257.7","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/acr.23201","article-title":"Clinical and serologic features in patients with incomplete lupus classification versus systemic lupus erythematosus patients and controls","volume":"69","author":"Aberle","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090312552378000_6.2.e001257.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.38006"},{"key":"2025090312552378000_6.2.e001257.9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.autrev.2019.05.011","article-title":"The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study","volume":"18","author":"Mageau","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025090312552378000_6.2.e001257.10","doi-asserted-by":"crossref","unstructured":"JJ W , VD D , MM S , et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; doi: 10.1111\/j.1523-1755.2004.00443.x","DOI":"10.1111\/j.1523-1755.2004.00443.x"},{"key":"2025090312552378000_6.2.e001257.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025090312552378000_6.2.e001257.12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664"},{"key":"2025090312552378000_6.2.e001257.13","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000266","article-title":"Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials","volume":"5","author":"Kim","year":"2018","journal-title":"Lupus Sci & Med"},{"key":"2025090312552378000_6.2.e001257.14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology (UK)"},{"key":"2025090312552378000_6.2.e001257.15","first-page":"2","article-title":"Outcomes of rituximab therapy in refractory lupus: a meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"2025090312552378000_6.2.e001257.16","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E09-07-0609"},{"key":"2025090312552378000_6.2.e001257.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-017-0153-7"},{"key":"2025090312552378000_6.2.e001257.18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/1566524011307010024","article-title":"Functions of S100 proteins","volume":"13","author":"Donato","year":"2012","journal-title":"Curr Mol Med"},{"key":"2025090312552378000_6.2.e001257.19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41584-018-0058-9","article-title":"S100 proteins in rheumatic diseases","volume":"14","author":"Austermann","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312552378000_6.2.e001257.20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0961203316655208","article-title":"Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus","volume":"26","author":"Tyd\u00e9n","year":"2017","journal-title":"Lupus"},{"key":"2025090312552378000_6.2.e001257.21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-017-1444-4","article-title":"Urine S100 proteins as potential biomarkers of lupus nephritis activity","volume":"19","author":"Turnier","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312552378000_6.2.e001257.22","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/rheumatology\/ket263","article-title":"Increased serum levels of S100A8\/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus","volume":"52","author":"Tyd\u00e9n","year":"2013","journal-title":"Rheumatology (UK)"},{"key":"2025090312552378000_6.2.e001257.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"2025090312552378000_6.2.e001257.24","doi-asserted-by":"crossref","unstructured":"Isenberg DA , Rahman A , Allen E , et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005. doi: 10.1093\/rheumatology\/keh624","DOI":"10.1093\/rheumatology\/keh624"},{"key":"2025090312552378000_6.2.e001257.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq026"},{"key":"2025090312552378000_6.2.e001257.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130030"},{"key":"2025090312552378000_6.2.e001257.27","first-page":"S85","article-title":"Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care","volume":"32","author":"Castrej\u00f3n","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312552378000_6.2.e001257.28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780400504","article-title":"Oral contraceptives and systemic lupus erythematosus","volume":"40","author":"Petri","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025090312552378000_6.2.e001257.29","unstructured":"R Core Team . R: a language and environment for statistical computing , 2019. Vienna, Austria. Available at: https:\/\/www.R-project.org\/."},{"key":"2025090312552378000_6.2.e001257.30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.40747","article-title":"Association of blood concentrations of complement split product iC3b and Serum C3 with systemic lupus erythematosus disease activity","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312552378000_6.2.e001257.31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1371\/journal.pone.0162000","article-title":"Blocking the interactions between calcium-bound S100A12 protein and the V domain of RAGE using tranilast","volume":"11","author":"Chiou","year":"2016","journal-title":"PLoS One"},{"key":"2025090312552378000_6.2.e001257.32","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22274"},{"key":"2025090312552378000_6.2.e001257.33","doi-asserted-by":"publisher","DOI":"10.1038\/nm1638"},{"key":"2025090312552378000_6.2.e001257.34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bbamcr.2008.11.016","article-title":"Binding of S100 proteins to RAGE: an update","volume":"1793","author":"Leclerc","year":"2009","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"key":"2025090312552378000_6.2.e001257.35","doi-asserted-by":"crossref","unstructured":"Idborg H , Zandian A , Ossipova E , et al. Circulating levels of interferon regulatory factor-5 associates with subgroups of systemic lupus erythematosus patients. Front Immunol 2019;10. doi: 10.3389\/fimmu.2019.01029","DOI":"10.3389\/fimmu.2019.01029"},{"key":"2025090312552378000_6.2.e001257.36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/481520","article-title":"Mechanisms of glomerular albumin filtration and tubular reabsorption","volume":"2012","author":"Tojo","year":"2012","journal-title":"Int J Nephrol"},{"key":"2025090312552378000_6.2.e001257.37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007801"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:55:31Z","timestamp":1756929331000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,28]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/rmdopen-2020-001257"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001257","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}